scutellarin has been researched along with Bone Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, G; Jian, M; Li, X; Liu, Z; Song, F; Sun, X; Wang, Z; Zhang, H | 1 |
| Li, H; Liu, Y; Wang, Z; Yan, J | 1 |
1 review(s) available for scutellarin and Bone Cancer
| Article | Year |
|---|---|
Discovery of Phenolic Matrix Metalloproteinase Inhibitors by Peptide Microarray for Osteosarcoma Treatment.
Topics: Animals; Antineoplastic Agents; Biological Products; Bone Neoplasms; Matrix Metalloproteinase 13; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Mice; Molecular Docking Simulation; Osteosarcoma; Peptides | 2022 |
1 other study(ies) available for scutellarin and Bone Cancer
| Article | Year |
|---|---|
Flavonoid compound breviscapine suppresses human osteosarcoma Saos-2 progression property and induces apoptosis by regulating mitochondria-dependent pathway.
Topics: Apoptosis; Bone Neoplasms; Cell Line, Tumor; Flavonoids; Humans; Mitochondria; Neoplasm Proteins; Osteosarcoma; Signal Transduction | 2021 |